# TCG Crossover Management, LLC 13F Q2 2026: $4.2 billion

TCG Crossover Management, LLC reported $4.2 billion in 13F securities across 54 positions for the quarter ended June 30, 2026, in a holdings report filed August 14, 2026. Its largest holding was Abivax SA at $801 million, 19.2% of the reported value. Since Q1 2026 it opened 12 new positions and exited 7.

SpecStream is the live web data engine for teams and agents. It reads the SEC's Form 13F data sets each quarter, and this page is that reading, keyed on the manager's CIK and the security's CUSIP. Ask for the managers or the holdings you track, and each new 13F filing arrives in your sheet, CRM, Slack or agent as the SEC publishes it.

- Quarter: Q2 2026, the quarter ended June 30, 2026
- Reported value: $4,160,526,316
- Positions: 54
- Filed: August 14, 2026
- Report type: 13F holdings report
- CIK: 1839948
- Form 13F file number: 028-22283
- Business address: 245 Lytton Ave., Suite 350, Palo Alto, CA 94301
- SEC filing: [0001214659-26-010290](https://www.sec.gov/Archives/edgar/data/1839948/000121465926010290/0001214659-26-010290-index.htm)
- Investment adviser record: [Form ADV on SpecStream](https://specstream.ai/data/investment-advisers/firm/tcg-crossover-management-llc-311718)

## Top 25 holdings by value

The largest of 54 positions by reported value at the end of the quarter ended June 30, 2026. Put and call options are marked in the class. Change is in shares or principal against the filing for the quarter ended March 31, 2026.

| Issuer | Class | Shares or principal | Value | Change since Q1 2026 |
| --- | --- | --- | --- | --- |
| [Abivax SA](https://specstream.ai/data/institutional-holders/abivax-sa-00370m103) | SPONSORED ADS | 6,007,834 | $800.6 million | -473,251 |
| [Tango Therapeutics Inc](https://specstream.ai/data/institutional-holders/tango-therapeutics-inc-87583x109) | COM | 9,081,201 | $283.9 million | -1,449,870 |
| [CG Oncology Inc](https://specstream.ai/data/institutional-holders/cg-oncology-inc-156944100) | COM | 3,670,206 | $260.8 million | No change |
| [Cogent Biosciences Inc](https://specstream.ai/data/institutional-holders/cogent-biosciences-inc-19240q201) | COM | 4,854,436 | $187.9 million | -92,458 |
| [Immunovant Inc](https://specstream.ai/data/institutional-holders/immunovant-inc-45258j102) | COM | 4,457,988 | $171.8 million | No change |
| [Spyre Therapeutics Inc](https://specstream.ai/data/institutional-holders/spyre-therapeutics-inc-00773j202) | COM NEW | 1,900,582 | $168.7 million | No change |
| [Dianthus Therapeutics Inc](https://specstream.ai/data/institutional-holders/dianthus-therapeutics-inc-252828108) | COM | 1,676,624 | $163.4 million | No change |
| [Mirum Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/mirum-pharmaceuticals-inc-604749101) | COM | 1,062,049 | $124.3 million | No change |
| [Zai Lab LTD](https://specstream.ai/data/institutional-holders/zai-lab-ltd-98887q104) | ADR | 6,137,627 | $116.6 million | New |
| [Amylyx Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/amylyx-pharmaceuticals-inc-03237h101) | COM | 6,243,812 | $112.1 million | No change |
| [Monte Rosa Therapeutics Inc](https://specstream.ai/data/institutional-holders/monte-rosa-therapeutics-inc-61225m102) | COM | 4,622,151 | $111.9 million | No change |
| [Biocryst Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/biocryst-pharmaceuticals-inc-09058v103) | COM | 11,020,968 | $110.2 million | No change |
| [Vor Biopharma Inc](https://specstream.ai/data/institutional-holders/vor-biopharma-inc-929033207) | COM NEW | 5,673,078 | $104.4 million | No change |
| [Tyra Biosciences Inc](https://specstream.ai/data/institutional-holders/tyra-biosciences-inc-90240b106) | COM | 3,248,980 | $103.8 million | No change |
| [Dyne Therapeutics Inc](https://specstream.ai/data/institutional-holders/dyne-therapeutics-inc-26818m108) | COM | 4,615,144 | $102.5 million | No change |
| [Disc Medicine Inc](https://specstream.ai/data/institutional-holders/disc-medicine-inc-254604101) | COM | 1,341,862 | $98.1 million | No change |
| [Relay Therapeutics Inc](https://specstream.ai/data/institutional-holders/relay-therapeutics-inc-75943r102) | COM | 4,273,356 | $80 million | No change |
| [Savara Inc](https://specstream.ai/data/institutional-holders/savara-inc-805111101) | COM | 12,362,205 | $76.2 million | No change |
| [Aura Biosciences Inc](https://specstream.ai/data/institutional-holders/aura-biosciences-inc-05153u107) | COM | 9,533,333 | $67.7 million | New |
| [Revolution Medicines Inc](https://specstream.ai/data/institutional-holders/revolution-medicines-inc-76155x100) | COM | 340,899 | $63.8 million | -235,574 |
| [First Tracks Biotherapeutics](https://specstream.ai/data/institutional-holders/first-tracks-biotherapeutics-337185102) | ORD SHS | 2,895,304 | $58.3 million | New |
| [Kodiak Sciences Inc](https://specstream.ai/data/institutional-holders/kodiak-sciences-inc-50015m109) | COM | 1,445,538 | $56.3 million | No change |
| [Avalo Therapeutics Inc](https://specstream.ai/data/institutional-holders/avalo-therapeutics-inc-05338f306) | COM NEW | 3,017,120 | $55.8 million | +2,278,737 |
| [LB Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/lb-pharmaceuticals-inc-50180m108) | COM SHS | 1,447,310 | $47 million | -392,179 |
| [Century Therapeutics Inc](https://specstream.ai/data/institutional-holders/century-therapeutics-inc-15673t100) | COM | 17,754,430 | $43.4 million | No change |

## New positions in Q2 2026

12 positions not in the filing for the quarter ended March 31, 2026.

| Issuer | Class | Shares or principal | Value |
| --- | --- | --- | --- |
| [Zai Lab LTD](https://specstream.ai/data/institutional-holders/zai-lab-ltd-98887q104) | ADR | 6,137,627 | $116.6 million |
| [Aura Biosciences Inc](https://specstream.ai/data/institutional-holders/aura-biosciences-inc-05153u107) | COM | 9,533,333 | $67.7 million |
| [First Tracks Biotherapeutics](https://specstream.ai/data/institutional-holders/first-tracks-biotherapeutics-337185102) | ORD SHS | 2,895,304 | $58.3 million |
| [Editas Medicine Inc](https://specstream.ai/data/institutional-holders/editas-medicine-inc-28106w103) | COM | 11,111,111 | $36 million |
| [Pharvaris N V](https://specstream.ai/data/institutional-holders/pharvaris-n-v-n69605108) | COM | 1,008,229 | $34.9 million |
| [Inflarx NV](https://specstream.ai/data/institutional-holders/inflarx-nv-n44821101) | COM | 14,500,000 | $32.5 million |
| [Altimmune Inc](https://specstream.ai/data/institutional-holders/altimmune-inc-02155h200) | COM NEW | 10,000,000 | $30.4 million |
| [Aktis Oncology Inc](https://specstream.ai/data/institutional-holders/aktis-oncology-inc-01021m104) | COM | 696,560 | $22.5 million |
| [Forte Biosciences Inc](https://specstream.ai/data/institutional-holders/forte-biosciences-inc-34962g208) | COM NEW | 920,000 | $19.6 million |
| [Research Alliance Corp III](https://specstream.ai/data/institutional-holders/research-alliance-corp-iii-g75226103) | ORD SHS CL A | 500,000 | $5.4 million |
| [Jatt II Acquisition Corp](https://specstream.ai/data/institutional-holders/jatt-ii-acquisition-corp-g50765109) | ORD SHS | 200,000 | $2.3 million |
| [Eikon Therapeutics Inc](https://specstream.ai/data/institutional-holders/eikon-therapeutics-inc-282564103) | COM | 37,902 | $494,621 |

## Positions exited in Q2 2026

7 positions in the filing for the quarter ended March 31, 2026 and not in this one, with the shares and value reported then.

| Issuer | Class | Shares or principal | Value |
| --- | --- | --- | --- |
| Centessa Pharmaceuticals PLC | SPONSORED ADS | 4,286,480 | $170.3 million |
| [Fulcrum Therapeutics Inc](https://specstream.ai/data/institutional-holders/fulcrum-therapeutics-inc-359616109) | COM | 5,250,000 | $40.3 million |
| [Liquidia Corporation](https://specstream.ai/data/institutional-holders/liquidia-corporation-53635d202) | COM NEW | 403,048 | $15.2 million |
| [Urogen Pharma LTD](https://specstream.ai/data/institutional-holders/urogen-pharma-ltd-m96088105) | COM | 405,365 | $7.3 million |
| [Structure Therapeutics Inc](https://specstream.ai/data/institutional-holders/structure-therapeutics-inc-86366e106) | SPONSORED ADS | 140,411 | $6.8 million |
| [Upstream Bio Inc](https://specstream.ai/data/institutional-holders/upstream-bio-inc-91678a107) | COM | 181,063 | $1.6 million |
| [Vistagen Therapeutics Inc](https://specstream.ai/data/institutional-holders/vistagen-therapeutics-inc-92840h400) | COM | 2,676,580 | $1.5 million |

## Also on SpecStream

- [TCG Crossover Management, LLC Form 13F filing on EDGAR](https://www.sec.gov/Archives/edgar/data/1839948/000121465926010290/0001214659-26-010290-index.htm)
- [TCG Crossover Management, LLC investment adviser record (Form ADV)](https://specstream.ai/data/investment-advisers/firm/tcg-crossover-management-llc-311718)
- [Largest 13F filers in California](https://specstream.ai/data/institutional-holdings/state/california)
- [Largest institutional managers by 13F value](https://specstream.ai/data/institutional-holdings)
- [Most widely held securities in 13F filings](https://specstream.ai/data/institutional-holders)

Source: [the SEC's Form 13F data sets](https://www.sec.gov/data-research/sec-markets-data/form-13f-data-sets). Public data published by the US Securities and Exchange Commission (US government work). Managers report these holdings themselves in Form 13F, and the SEC does not check or guarantee them. Form 13F lists long positions in US listed equities, some options and convertible notes held at the end of the quarter, and leaves out short positions, cash, most bonds and holdings below the reporting threshold. Values are market values in US dollars as the manager filed them. A manager can ask the SEC to keep some positions confidential for a time. This page uses SEC data and is not endorsed or certified by the SEC.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in Palo Alto, California

- [Legal services firms in Palo Alto, California](https://specstream.ai/data/businesses/legal-services-firms/palo-alto-california-united-states)
- [Coffee shops in Palo Alto, California](https://specstream.ai/data/businesses/coffee-shops/palo-alto-california-united-states)
- [Law firms in Palo Alto, California](https://specstream.ai/data/businesses/law-firms/palo-alto-california-united-states)
- [Business consulting firms in Palo Alto, California](https://specstream.ai/data/businesses/business-consulting-firms/palo-alto-california-united-states)
- [IT companies in Palo Alto, California](https://specstream.ai/data/businesses/it-companies/palo-alto-california-united-states)
- [Biotechnology companies in Palo Alto, California](https://specstream.ai/data/businesses/biotechnology-companies/palo-alto-california-united-states)
